Literature DB >> 9597241

Vancomycin-resistant and vancomycin-susceptible enterococcal bacteremia: comparison of clinical features and outcomes.

G M Lucas1, N Lechtzin, D W Puryear, L L Yau, C W Flexner, R D Moore.   

Abstract

Vancomycin-resistant Enterococcus (VRE) is a major nosocomial pathogen. We collected clinical and laboratory data on 93 hospitalized adults with VRE bacteremia and 101 adults with vancomycin-susceptible enterococcal (VSE) bacteremia. Risk factors for VRE bacteremia included central venous catheterization, hyperalimentation, and prolonged hospitalization prior to the initial blood culture. VRE-infected patients were less likely to have undergone recent surgery or have polymicrobial bacteremia, suggesting a pathogenesis distinct from traditional VSE bacteremia. Prior exposure to metronidazole was the only significant pharmacologic risk factor for VRE bacteremia. Animal studies suggest metronidazole potentiates enterococcal overgrowth in the gastrointestinal tract and translocation into the bloodstream. An increasing APACHE II score was the major risk factor for death in a multivariate analysis, with VRE status being of only borderline significance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597241     DOI: 10.1086/520311

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  33 in total

1.  Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients.

Authors:  C J Donskey; T K Chowdhry; M T Hecker; C K Hoyen; J A Hanrahan; A M Hujer; R A Hutton-Thomas; C C Whalen; R A Bonomo; L B Rice
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

Review 2.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Association between vancomycin-resistant Enterococci bacteremia and ceftriaxone usage.

Authors:  James A McKinnell; Danielle F Kunz; Eric Chamot; Mukesh Patel; Rhett M Shirley; Stephen A Moser; John W Baddley; Peter G Pappas; Loren G Miller
Journal:  Infect Control Hosp Epidemiol       Date:  2012-05-14       Impact factor: 3.254

Review 4.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

5.  Evaluation of biosite triage Clostridium difficile panel for rapid detection of Clostridium difficile in stool samples.

Authors:  M L Landry; J Topal; D Ferguson; D Giudetti; Y Tang
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Vancomycin-resistant enterococci in Canada revisited.

Authors:  B L Johnston; J M Conly
Journal:  Can J Infect Dis       Date:  2000-05

7.  Multi-drug-resistant gram-negative bacterial infection in surgical patients hospitalized in the ICU: a cohort study.

Authors:  V G Alexiou; A Michalopoulos; G C Makris; G Peppas; G Samonis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-28       Impact factor: 3.267

Review 8.  Hospital epidemiology and infection control in acute-care settings.

Authors:  Emily R M Sydnor; Trish M Perl
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

9.  Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study.

Authors:  Genovefa A Papanicolaou; Celalettin Ustun; Jo-Anne H Young; Min Chen; Soyoung Kim; Kwang Woo Ahn; Krishna Komanduri; Caroline Lindemans; Jeffery J Auletta; Marcie L Riches
Journal:  Clin Infect Dis       Date:  2019-10-30       Impact factor: 9.079

10.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.